KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
KMT2C
MYC
Metastasis
Prostate cancer
Senescence
p16INK4A
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
30 03 2022
30 03 2022
Historique:
received:
27
12
2021
accepted:
17
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C have been detected by whole exome sequencing studies in various cancers, including malignancies of the prostate. However, the biological consequences of these alterations in prostate cancer have not yet been elucidated. To investigate the functional effects of these mutations, we deleted the C-terminal catalytic core motif of Kmt2c specifically in mouse prostate epithelium. We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients. We show here for the first time that impaired KMT2C methyltransferase activity drives proliferation and PIN formation and, when combined with loss of the tumour suppressor PTEN, triggers loss of senescence, metastatic dissemination and dramatically reduces life expectancy. In Kmt2c-mutated tumours we show enrichment of proliferative MYC gene signatures and loss of expression of the cell cycle repressor p16 We identified truncating events of KMT2C as drivers of proliferation and PIN formation. Loss of PTEN and KMT2C in prostate cancer results in loss of senescence, metastatic dissemination and reduced life expectancy. Our data demonstrate the prognostic significance of KMT2C mutation status in prostate cancer patients. Inhibition of the MYC signalling axis may be a viable treatment option for patients with KMT2C truncations and therefore poor prognosis.
Sections du résumé
BACKGROUND
Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C have been detected by whole exome sequencing studies in various cancers, including malignancies of the prostate. However, the biological consequences of these alterations in prostate cancer have not yet been elucidated.
METHODS
To investigate the functional effects of these mutations, we deleted the C-terminal catalytic core motif of Kmt2c specifically in mouse prostate epithelium. We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients.
RESULTS
We show here for the first time that impaired KMT2C methyltransferase activity drives proliferation and PIN formation and, when combined with loss of the tumour suppressor PTEN, triggers loss of senescence, metastatic dissemination and dramatically reduces life expectancy. In Kmt2c-mutated tumours we show enrichment of proliferative MYC gene signatures and loss of expression of the cell cycle repressor p16
CONCLUSIONS
We identified truncating events of KMT2C as drivers of proliferation and PIN formation. Loss of PTEN and KMT2C in prostate cancer results in loss of senescence, metastatic dissemination and reduced life expectancy. Our data demonstrate the prognostic significance of KMT2C mutation status in prostate cancer patients. Inhibition of the MYC signalling axis may be a viable treatment option for patients with KMT2C truncations and therefore poor prognosis.
Identifiants
pubmed: 35354467
doi: 10.1186/s12943-022-01542-8
pii: 10.1186/s12943-022-01542-8
pmc: PMC8966196
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
DNA-Binding Proteins
0
KMT2C protein, human
0
Methyltransferases
EC 2.1.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
89Informations de copyright
© 2022. The Author(s).
Références
Nat Genet. 2009 May;41(5):619-24
pubmed: 19396168
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Urol. 2021 Feb;18(2):79-92
pubmed: 33328650
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):E3506-15
pubmed: 23918374
Bioinformatics. 2012 Aug 15;28(16):2184-5
pubmed: 22743226
Nat Rev Cancer. 2015 Jul;15(7):397-408
pubmed: 26105537
Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
Nat Rev Genet. 2016 May;17(5):284-99
pubmed: 26972587
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2019 Aug;19(8):439-453
pubmed: 31235879
PLoS Biol. 2003 Dec;1(3):E59
pubmed: 14691534
Nat Rev Genet. 2019 Aug;20(8):434-435
pubmed: 31160791
Nat Genet. 2003 Jan;33(1):49-54
pubmed: 12469122
ScientificWorldJournal. 2012;2012:842727
pubmed: 22654636
Clin Epigenetics. 2020 Jan 10;12(1):10
pubmed: 31924266
Eur Urol. 2020 Nov;78(5):671-679
pubmed: 32317181
Mol Cancer. 2021 Jan 4;20(1):3
pubmed: 33397405
Clin Breast Cancer. 2017 Jun;17(3):e135-e142
pubmed: 27986439
Semin Cancer Biol. 2018 Aug;51:149-159
pubmed: 28807546
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Immunity. 2001 May;14(5):523-34
pubmed: 11371355
Cancer Cell. 2021 Jan 11;39(1):68-82.e9
pubmed: 33186519
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Rev Cancer. 2015 Jun;15(6):334-46
pubmed: 25998713
Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15392-7
pubmed: 17021013
Int J Mol Sci. 2020 Oct 18;21(20):
pubmed: 33081056
Nature. 2005 Aug 4;436(7051):725-30
pubmed: 16079851
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Nucleic Acids Res. 2021 Jan 8;49(D1):D884-D891
pubmed: 33137190
Sci Signal. 2009 Aug 18;2(84):ra44
pubmed: 19690330
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Protoc. 2016 Feb;11(2):347-58
pubmed: 26797458
Oncogene. 2019 Jun;38(25):4977-4989
pubmed: 30820039
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Nature. 2011 Feb 10;470(7333):269-73
pubmed: 21289624
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10823-8
pubmed: 11535819
Nat Rev Cancer. 2010 Jan;10(1):51-7
pubmed: 20029423
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
J Clin Invest. 2010 Mar;120(3):681-93
pubmed: 20197621
Genes Cancer. 2010 Jun;1(6):617-28
pubmed: 21779461
Mod Pathol. 2008 Sep;21(9):1156-67
pubmed: 18567993
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Genet. 2018 May;50(5):645-651
pubmed: 29610475
Cancer Res. 2016 Aug 15;76(16):4861-71
pubmed: 27280393
Cancer Cell. 2003 Sep;4(3):223-38
pubmed: 14522256
Nat Biotechnol. 2019 Apr;37(4):367-369
pubmed: 30877282
Cancer Cell. 2003 Sep;4(3):209-21
pubmed: 14522255
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
F1000Res. 2018 Aug 24;7:1338
pubmed: 30254741
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Cancer Lett. 2019 Aug 28;458:56-65
pubmed: 31128216
Nat Med. 2018 Jun;24(6):758-769
pubmed: 29785026
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Oncogene. 2018 Aug;37(34):4692-4710
pubmed: 29755131
J Exp Med. 2018 Jun 4;215(6):1749-1763
pubmed: 29743291
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Cancer. 2020 Nov;1(11):1082-1096
pubmed: 34085047
Science. 2017 Mar 24;355(6331):1324-1330
pubmed: 28336670
Cancer Res. 2016 Jan 15;76(2):283-92
pubmed: 26554830
Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22
pubmed: 20841388
Mech Dev. 2001 Mar;101(1-2):61-9
pubmed: 11231059
Nat Rev Cancer. 2020 Feb;20(2):74-88
pubmed: 31686003
Cancer Res. 2012 Sep 15;72(18):4765-76
pubmed: 22836754
Prostate Cancer Prostatic Dis. 2010 Dec;13(4):311-5
pubmed: 20820186